Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
26.40
+0.18 (0.69%)
Nov 21, 2024, 4:00 PM EST - Market closed
Royalty Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 2,266 | 2,355 | 2,237 | 2,289 | 2,122 | 1,814 | Upgrade
|
| Revenue Growth (YoY) | -2.51% | 5.24% | -2.28% | 7.87% | 16.98% | 1.08% | Upgrade
|
| Cost of Revenue | 491.91 | 560.66 | 904.24 | 452.84 | 230.84 | -1,019 | Upgrade
|
| Gross Profit | 1,774 | 1,794 | 1,333 | 1,837 | 1,892 | 2,834 | Upgrade
|
| Selling, General & Admin | 228.27 | 249.75 | 227.3 | 182.83 | 181.72 | 103.44 | Upgrade
|
| Research & Development | 2 | 52 | 177.11 | 200.08 | 26.29 | 83.04 | Upgrade
|
| Operating Expenses | 230.27 | 301.75 | 410.08 | 405.91 | 231.06 | 210.4 | Upgrade
|
| Operating Income | 1,544 | 1,492 | 922.89 | 1,431 | 1,660 | 2,623 | Upgrade
|
| Interest Expense | -207.01 | -187.19 | -187.96 | -166.14 | -167.96 | -341.19 | Upgrade
|
| Interest & Investment Income | 44.81 | 72.29 | 78.34 | 53.54 | 28.38 | 22.33 | Upgrade
|
| Earnings From Equity Investments | -1.77 | 28.88 | -8.97 | -19.49 | 44.46 | -32.52 | Upgrade
|
| Other Non Operating Income (Expenses) | -14.65 | -24.03 | 81.86 | -27.21 | -33.5 | 33.87 | Upgrade
|
| EBT Excluding Unusual Items | 1,365 | 1,382 | 886.15 | 1,271 | 1,532 | 2,306 | Upgrade
|
| Gain (Loss) on Sale of Investments | 348.84 | 317.98 | -40.26 | -30.21 | 265.67 | 155.75 | Upgrade
|
| Asset Writedown | - | - | -615.83 | - | -65.05 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -30.5 | - | Upgrade
|
| Pretax Income | 1,714 | 1,700 | 230.06 | 1,241 | 1,702 | 2,461 | Upgrade
|
| Earnings From Continuing Operations | 1,714 | 1,700 | 230.06 | 1,241 | 1,702 | 2,461 | Upgrade
|
| Minority Interest in Earnings | -568.94 | -565.25 | -187.23 | -621.47 | -726.91 | -112.88 | Upgrade
|
| Net Income | 1,145 | 1,135 | 42.83 | 619.73 | 975.04 | 2,349 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 479.84 | - | Upgrade
|
| Net Income to Common | 1,145 | 1,135 | 42.83 | 619.73 | 495.2 | 2,349 | Upgrade
|
| Net Income Growth | 520.96% | 2549.50% | -93.09% | -36.44% | -58.48% | 70.46% | Upgrade
|
| Shares Outstanding (Basic) | 448 | 448 | 438 | 415 | 375 | - | Upgrade
|
| Shares Outstanding (Diluted) | 596 | 603 | 438 | 415 | 375 | - | Upgrade
|
| Shares Change (YoY) | 33.46% | 37.66% | 5.59% | 10.48% | - | - | Upgrade
|
| EPS (Basic) | 2.55 | 2.54 | 0.10 | 1.49 | 1.32 | - | Upgrade
|
| EPS (Diluted) | 2.55 | 2.53 | 0.10 | 1.49 | 1.32 | - | Upgrade
|
| EPS Growth | 518.56% | 2490.73% | -93.44% | 12.97% | - | - | Upgrade
|
| Free Cash Flow | 2,799 | 2,988 | 2,144 | 2,018 | 2,035 | 1,667 | Upgrade
|
| Free Cash Flow Per Share | 4.70 | 4.96 | 4.90 | 4.86 | 5.42 | - | Upgrade
|
| Dividend Per Share | 0.830 | 0.800 | 0.760 | 0.680 | 0.300 | - | Upgrade
|
| Dividend Growth | 5.06% | 5.26% | 11.76% | 126.67% | - | - | Upgrade
|
| Gross Margin | 78.29% | 76.19% | 59.58% | 80.22% | 89.12% | 156.18% | Upgrade
|
| Operating Margin | 68.13% | 63.37% | 41.25% | 62.49% | 78.24% | 144.59% | Upgrade
|
| Profit Margin | 50.53% | 48.20% | 1.91% | 27.07% | 23.33% | 129.45% | Upgrade
|
| Free Cash Flow Margin | 123.53% | 126.89% | 95.83% | 88.12% | 95.87% | 91.90% | Upgrade
|
| EBITDA | - | 1,498 | 928.56 | 1,454 | 1,684 | 2,647 | Upgrade
|
| EBITDA Margin | - | 63.61% | 41.51% | 63.50% | 79.32% | 145.91% | Upgrade
|
| D&A For EBITDA | - | 5.67 | 5.67 | 23 | 23.06 | 23.92 | Upgrade
|
| EBIT | 1,544 | 1,492 | 922.89 | 1,431 | 1,660 | 2,623 | Upgrade
|
| EBIT Margin | 68.13% | 63.37% | 41.25% | 62.49% | 78.24% | 144.59% | Upgrade
|
| Revenue as Reported | 2,266 | 2,355 | 2,237 | 2,289 | 2,122 | 1,814 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.